TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product

Trudy Straetemans, Anke Janssen, Koen Jansen, Ruud Doorn, Tineke Aarts, Anna D D van Muyden, Marieke Simonis, Judith Bergboer, Moniek de Witte, Zsolt Sebestyen, Jurgen Kuball

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Straetemans and colleagues characterized αβT cells engineered to express a defined γδT cell receptor (TEG001) used in a first-in-human clinical study, with TLA in combination with NGS and qPCR. They provide a rapid strategy to evaluate the presence, integrity, and persistence of genetic information along the production chain of any GTMP.

Original languageEnglish
Pages (from-to)561-571
Number of pages11
JournalMolecular Therapy
Volume28
Issue number2
Early online date14 Dec 2019
DOIs
Publication statusPublished - 5 Feb 2020

Keywords

  • engineered T cells
  • gene therapy medicinal product
  • GTMP
  • targeted locus amplification
  • TEG001
  • TLA
  • vector copy number
  • γδT cells

Fingerprint

Dive into the research topics of 'TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product'. Together they form a unique fingerprint.

Cite this